Anagrelide
From Wikipedia, the free encyclopedia
 |
|
|
Anagrelide
|
|
| Systematic (IUPAC) name | |
| 6,7-dichloro-1,5-dihydroimidazo (2,1-b)quinazolin-2(3H)-one |
|
| Identifiers | |
| CAS number | 2182 |
| ATC code | L01XX35 |
| PubChem | 2182 |
| DrugBank | APRD00798 |
| Chemical data | |
| Formula | C10H7N3Cl2O |
| Mol. weight | 256.088 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Anagrelide (Agrylin®/Xagrid®, Shire) is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia).
Contents |
[edit] Mechanism
It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 = 36nM) inhibitor of phosphodiesterase-III.
[edit] Uses
According to a 2005 Medical Research Council trial, the combination of hydroxyurea with aspirin is superior to the combination of anagrelide and aspirin for the initial management of ET, with a small increase in the number of cases of myelofibrosis.[1]
[edit] Side-effects
Common side effects are headache, diarrhea, unusual weakness, nausea and dizziness.
[edit] Reference
- ^ Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45. PMID 16000354.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
